Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies

被引：0
|
作者：
Skuban, Aleksandar [1 ]
Kane, John M. [2 ]
Ouyang, John [1 ]
Weiss, Catherine [1 ]
Weiller, Emmanuelle [3 ]
Correll, Christoph U. [2 ]
机构：
[1] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA
[2] Zucker Hillside Hosp, Glen Oaks, NY USA
[3] H Lundbeck & Co AS, Valby, Denmark
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM421
引用
收藏
页码：202 / 202
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
    Correll, C.
    Skuban, A.
    Ouyang, J.
    Weiss, C.
    Weiller, E.
    Kane, J. M.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S522 - S523
  • [2] EFFICACY OF BREXPIPRAZOLE (OPC-34712) IN ACUTE SCHIZOPHRENIA: RESULTS OF TWO POOLED PIVOTAL STUDIES
    Skuban, Aleksandar
    Correll, Christoph Ulrich
    Kane, John M.
    Ouyang, John
    Weiss, Catherine
    Weiller, Emmanuelle
    [J]. SCHIZOPHRENIA BULLETIN, 2015, 41 : S333 - S334
  • [3] Efficacy and Safety of Adjunctive Brexpiprazole (OPC-34712) in Major Depressive Disorder: Results: of Two Pivotal Clinical Studies
    Thase, Michael
    Youakim, James
    Skuban, Alexander
    Hobart, Mary
    Zhang, Peter
    Legacy, Susan
    McQuade, Robert
    Nyilas, Margaretta
    Carson, William
    Sanchez, Raymond
    [J]. NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S357 - S357
  • [4] Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies
    Eriksson, Hans
    Weiller, Emmanuelle
    Weiss, Catherine
    Zhang, Peter
    Skuban, Aleksandar
    Thase, Michael E.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 102 - 102
  • [5] EFFICACY AND SAFETY OF BREXPIPRAZOLE IN ACUTE SCHIZOPHRENIA: A POLED ANALYSIS OF TWO PIVOTAL STUDIES
    Skuban, A.
    Oyang, J.
    Hobart, M.
    Eriksson, H.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 152 - 153
  • [6] The Effect of Brexpiprazole (OPC-34712) versus Aripiprazole in Adult Patients with Acute Schizophrenia: An Exploratory Study
    Citrome, Leslie
    Ota, Ai
    Nagamizu, Kazuhiro
    Perry, Pamela
    Weiller, Emmanuelle
    Baker, Ross
    [J]. BIOLOGICAL PSYCHIATRY, 2015, 77 (09)
  • [7] The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study
    Citrome, Leslie
    Ota, Ai
    Nagamizu, Kazuhiro
    Perry, Pamela
    Weiller, Emmanuelle
    Baker, Ross
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 189 - 190
  • [8] Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies
    Correll, Christoph U.
    Skuban, Aleksandar
    Ouyang, John
    Weiller, Emmanuelle
    Weiss, Catherine
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 190 - 190
  • [9] LONG-TERM SAFETY OF BREXPIPRAZOLE (OPC-34712) IN SCHIZOPHRENIA: RESULTS FROM TWO 52-WEEK OPEN-LABEL STUDIES
    Correll, Christoph Ulrich
    Skuban, Aleksandar
    Ouyang, John
    Weiller, Emmanuelle
    Weiss, Catherine
    [J]. SCHIZOPHRENIA BULLETIN, 2015, 41 : S307 - S307
  • [10] Adjunctive Brexpiprazole (OPC-34712) in Patients with MDD and Anxiety Symptoms: Results from Post-Hoc Analyses of Two Pivotal Studies
    Kostic, Dusan
    Weiller, Emmanuelle
    Zhang, Peter
    Eramo, Anna
    Duffy, Ruth A.
    Baker, Ross A.
    Weiss, Catherine
    [J]. NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S163 - S163
12345